Intrinsic Capacity Biomarkers for Healthy Aging Assessment

Abstract

Intrinsic capacity, a composite of all the physical and mental capacities an individual can draw upon, is emerging as a pivotal concept in the paradigm of healthy aging. Biomarkers that accurately reflect intrinsic capacity are of significant clinical interest, as they provide objective tools for assessing aging trajectories, predicting adverse outcomes, and guiding interventions. This review synthesizes current evidence on intrinsic capacity biomarkers, elaborates their clinical utility, and discusses their integration into routine geriatric assessment to promote personalized and preventive medicine in older adults.

Introduction

The concept of intrinsic capacity, as proposed by the World Health Organization (WHO), shifts the focus from disease-centered models to function-based approaches in aging research. Intrinsic capacity encompasses multiple domains including cognition, locomotion, vitality, sensory function, and psychological well-being. Identifying reliable biomarkers for these domains is crucial for early detection of decline, individual risk stratification, and the implementation of preventive strategies. This article reviews the landscape of intrinsic capacity biomarkers, examining their clinical relevance and potential to transform geriatric care.

Epidemiology / Disease Burden

Globally, the population aged 65 and above is projected to nearly double by 2050, with a concomitant rise in chronic diseases and functional decline. Functional impairment is associated with increased morbidity, mortality, and healthcare utilization. Traditional disease-based metrics inadequately capture the heterogeneity of aging; therefore, intrinsic capacity offers a more nuanced approach to evaluating health in older adults. Epidemiological studies link diminished intrinsic capacity with higher risks of disability, loss of independence, and institutionalization, underscoring the urgent need for robust biomarkers in clinical settings.

Pathophysiology

Intrinsic capacity is determined by the complex interplay of genetic, metabolic, inflammatory, and environmental factors. Age-related changes in cellular senescence, mitochondrial dysfunction, chronic inflammation (inflammaging), and neuroendocrine dysregulation contribute to the decline across intrinsic capacity domains. For instance, increased levels of inflammatory cytokines correlate with frailty, while oxidative stress markers are linked to cognitive and physical decline. Biomarkers reflecting these underlying mechanisms hold promise as early indicators of compromised intrinsic capacity.

Risk Factors

Numerous risk factors accelerate the loss of intrinsic capacity, including multimorbidity, polypharmacy, sedentary lifestyle, malnutrition, social isolation, and genetic predisposition. Chronic diseases such as diabetes, cardiovascular disease, and neurodegenerative disorders further exacerbate functional decline. Psychosocial factors, including depression and low educational attainment, also influence the trajectory of intrinsic capacity. Identifying individuals at high risk through biomarker-based screening enables timely intervention and targeted prevention strategies.

Clinical Features

Decline in intrinsic capacity manifests as subtle or overt deficits across multiple domains: impaired gait and balance, reduced muscle strength, cognitive deterioration, sensory loss, and diminished psychological resilience. Early clinical features may include slower walking speed, lower grip strength, memory complaints, and reduced vitality. These features often precede overt disability and are best captured through a combination of clinical assessment and biomarker evaluation.

Diagnosis

Assessment of intrinsic capacity relies on a multidimensional approach. Traditional tools such as gait speed, handgrip dynamometry, cognitive tests, and sensory assessments are increasingly being complemented by laboratory and imaging biomarkers. Promising biomarkers include serum inflammatory markers (CRP, IL-6), neurofilament light chain for neurodegeneration, hormonal markers (DHEA-S), telomere length, and advanced imaging (MRI volumetrics for brain and muscle mass). Composite biomarker panels may offer superior sensitivity and specificity for diagnosing early decline in intrinsic capacity.

Treatment & Management

Interventions to preserve or restore intrinsic capacity are multifaceted and must be tailored to individual profiles. Exercise programs, nutritional optimization, cognitive training, and management of chronic diseases are central to maintaining functional capacity. Pharmacological interventions targeting underlying pathophysiological processes, such as anti-inflammatory agents or senolytics, are under investigation. Monitoring biomarker trajectories allows for personalization of care and timely adjustment of interventions to optimize outcomes.

Recent Advances / Emerging Therapies

Recent research has identified novel biomarkers such as circulating microRNAs, metabolomic signatures, and epigenetic markers that are associated with aging-related decline. Wearable technology and digital biomarkers provide real-time data on mobility and physiological parameters, enhancing the precision of intrinsic capacity assessment. Additionally, omics-based profiling and artificial intelligence hold promise for integrating multidimensional biomarker data to refine risk stratification and predict response to interventions.

Guideline Recommendations

International guidelines increasingly advocate for the incorporation of intrinsic capacity assessments in routine geriatric care. The WHO recommends periodic evaluation of intrinsic capacity domains, supported by biomarker data where available, to guide preventive and therapeutic strategies. Guidelines emphasize the need for standardized, validated biomarker panels and call for further research to establish normative reference ranges and clinical thresholds.

Conclusion

Intrinsic capacity biomarkers represent a transformative advancement in the assessment and management of healthy aging. By providing objective, mechanistic insights into functional decline, these biomarkers enable more precise risk stratification, early intervention, and personalized care for older adults. Continued research into novel biomarkers and their integration into clinical practice is essential for realizing the full potential of the intrinsic capacity framework in promoting healthy longevity.